Literature DB >> 8453962

The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man.

R Koopmans1, B Oosterhuis, J M Karemaker, J Wemer, C J van Boxtel.   

Abstract

We have studied the effect of dosage time of oxprenolol (Trasicor) on its pharmacokinetics and pharmacodynamics in six healthy volunteers. The drug effects measured were heart rate and systolic blood pressure during exercise. Oxprenolol was taken orally at 08.00 h, 14.00 h, 20.00 h, and 02.00 h in randomized order, with 1 week between successive doses. There were differences in the pharmacokinetics of oxprenolol for the ratio between the apparent volume of distribution and systemic availability (P = 0.04) and for elimination half-life (P = 0.006). Both were lowest after administration at 14.00 h (163 (77) l and 1.2 (0.6) h; mean (SD)) and highest after administration at 02.00 h (229 (100) l, and 1.7 (0.6) h). The systolic blood pressure during exercise before oxprenolol did not vary with dosage time, but heart rate during exercise before intake was lowest before dosage time 08.00 h and highest before dosage time 20.00 h (P = 0.03). The time-course of heart rate during exercise after oxprenolol was described by a model that incorporated the factors drug concentration and spontaneous diurnal variation. EC50 and Emax did not vary between dosage times. The spontaneous diurnal variation in heart rate during exercise was unaffected by oxprenolol, leading to an apparently greater effect of oxprenolol during the night than during the day.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453962     DOI: 10.1007/bf00315476

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Physical activity and the circadian rhythm of blood pressure.

Authors:  S Mann; M W Craig; D I Melville; V Balasubramanian; E B Raftery
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

3.  Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.

Authors:  B Lemmer; H Winkler; T Ohm; M Fink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

4.  Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment.

Authors:  S Mann; M W Craig; V Balasubramanian; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

5.  Diurnal patterns of blood pressure, heart rate and vasoactive hormones in normal man.

Authors:  A M Richards; M G Nicholls; E A Espiner; H Ikram; M Cullens; D Hinton
Journal:  Clin Exp Hypertens A       Date:  1986

6.  Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity.

Authors:  J A Panza; S E Epstein; A A Quyyumi
Journal:  N Engl J Med       Date:  1991-10-03       Impact factor: 91.245

7.  Circadian changes in estimated hepatic blood flow in healthy subjects.

Authors:  B Lemmer; G Nold
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

8.  Propranolol LA and ambulatory blood pressure.

Authors:  S Mann; M W Craig; V Balasubramanian; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  Stress hormonal response to exercise after sleep loss.

Authors:  B J Martin; P R Bender; H Chen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986

10.  Circadian rhythms and coronary artery disease.

Authors:  M B Rocco; E G Nabel; A P Selwyn
Journal:  Am J Cardiol       Date:  1987-03-09       Impact factor: 2.778

View more
  1 in total

1.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.